South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs
The Gauteng Division of the High Court in Pretoria granted an interim order preventing pharmacy group iDexis and its director from producing, supplying or marketing semaglutide products until regulators complete ongoing investigations and further legal proceedings are concluded. The case centres on semaglutide, one of the world’s most sought-after pharmaceutical ingredients. Semaglutide is the active ingredient in Novo Nordisk’s diabetes drug Oz…
SA court bars iDexis from selling compounded Ozempic
South Africa’s High Court has granted Novo Nordisk an interim interdict barring a local pharmacy group from manufacturing and selling compounded weight-loss medicines containing semaglutide, in a ruling that shows tightening scrutiny of unregistered drugs. The Gauteng Division of the High Court in Pretoria ruled on Monday that iDexis and its director must immediately stop compounding, supplying and marketing semaglutide-based products pending th…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
